Clinical Trials
3 trialsNCT04300556 2026-06-04
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Eisai Inc.
Phase 1/2 Recruiting
NCT00519285 2016-07-22
VENICE
Sanofi
Phase 3 Completed
NCT00822809 2012-10-03
CASIMAS
Neovii Biotech
Phase 3 Completed